CoChat

Versican in inflammation and tissue remodeling: The impact on lung disorders

Open access
Andersson-Sjoland, A., Hallgren, O., Rolandsson, S., Weitoft, M., Tykesson, E., Larsson-Callerfelt, A.-K., Rydell-Tormanen, K., Bjermer, L., Malmstrom, A., Karlsson, J. C., Westergren-Thorsson, G. · 2015 · Glycobiology

The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.

Abstract

Versican is a proteoglycan that has many different roles in tissue homeostasis and inflammation. The biochemical structure comprises four different types of the core protein with attached glycosaminoglycans (GAGs) that can be sulfated to various extents and has the capacity to regulate differentiation of different cell types, migration, cell adhesion, proliferation, tissue stabilization and inflammation. Versican's regulatory properties are of importance during both homeostasis and changes that lead to disease progression. The GAGs that are attached to the core protein are of the chondroitin sulfate/dermatan sulfate type and are known to be important in inflammation through interactions with cytokines and growth factors. For a more complex understanding of versican, it is of importance to study the tissue niche, where the wound healing process in both healthy and diseased conditions take place. In previous studies, our group has identified changes in the amount of the multifaceted versican in chronic lung disorders such as asthma, chronic obstructive pulmonary disease, and bronchiolitis obliterans syndrome, which could be a result of pathologic, transforming growth factor β driven, on-going remodeling processes. Reversely, the context of versican in its niche is of great importance since versican has been reported to have a beneficial role in other contexts, e.g. emphysema. Here we explore the vast mechanisms of versican in healthy lung and in lung disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/glycob/cwu120

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Events involving versican in the development of lung disease (e.g. COPD). (A) As a response to tissue damage and the cytokine/chemokine milieu (dots), mesenchymal (fibroblasts) and inflammatory (monocytes) cells migrate towards injury, and progenitor cells (MSC and fibrocytes) are recruited locally or from the circulation. (B) As a result, among other ECM molecules, versican is deposited in the lung tissue, increasing the reserve of cytokines/chemokines that perpetuate the recruitment of inflammatory cells. (C) Versican is involved in the differentiation of cells as depicted color coded (monocyte to macrophage, MSC to fibroblast and fibrocyte to myofibroblast. (D) Immunohistochemistry visualizes the deposition of versican (brown colors, arrow heads) in lung parenchyma from COPD patients.
Fig. 1. Events involving versican in the development of lung disease (e.g. COPD). (A) As a response to tissue damage and the cytokine/chemokine milieu (dots), mesenchymal (fibroblasts) and inflammatory (monocytes) cells migrate towards injury, and progenitor cells (MSC and fibrocytes) are recruited locally or from the circulation. (B) As a result, among other ECM molecules, versican is deposited in the lung tissue, increasing the reserve of cytokines/chemokines that perpetuate the recruitment of inflammatory cells. (C) Versican is involved in the differentiation of cells as depicted color coded (monocyte to macrophage, MSC to fibroblast and fibrocyte to myofibroblast. (D) Immunohistochemistry visualizes the deposition of versican (brown colors, arrow heads) in lung parenchyma from COPD patients.CC BY-NC · PubMed Central
Fig. 2. Structure of versican and its splice variants. Versican has globular domains at the N- (G1) and C-terminal (G3). The G1 contains an Ig-like domain, and an HABR; the G3 contains two EGF repeats; a LC; and a CRP-like motif. Between G1 and G3, CS/DS-binding sites attach GAG side chains to a various extent depending on splice variant (V0, V1, V2 and V3).
Fig. 2. Structure of versican and its splice variants. Versican has globular domains at the N- (G1) and C-terminal (G3). The G1 contains an Ig-like domain, and an HABR; the G3 contains two EGF repeats; a LC; and a CRP-like motif. Between G1 and G3, CS/DS-binding sites attach GAG side chains to a various extent depending on splice variant (V0, V1, V2 and V3).CC BY-NC · PubMed Central
Fig. 3. Graph shows that versican production is increased in lung-transplanted patients, asthma (controlled) and COPD compared with healthy controls. **P < 0.01, ***P < 0.005 compared with controls.
Fig. 3. Graph shows that versican production is increased in lung-transplanted patients, asthma (controlled) and COPD compared with healthy controls. **P < 0.01, ***P < 0.005 compared with controls.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 101 references

Research works printed but not linked: 22

  1. 2012, European Respiratory Journal, 40, 1362, 10.1183/09031936.00192611 · DOI · Paper page
  2. 2008, European Respiratory Journal, 32, 61, 10.1183/09031936.00147807 · DOI · Paper page
  3. 2012, Annals of the Rheumatic Diseases, 71, 761, 10.1136/annrheumdis-2011-200568 · DOI · Paper page
  4. 2008, European Respiratory Journal, 31, 998, 10.1183/09031936.00017207 · DOI · Paper page
  5. 2012, Journal of Biological Chemistry, 287, 14122, 10.1074/jbc.m111.324988 · DOI · Paper page
  6. 2012, Annals of the Rheumatic Diseases, 72, 1575
  7. 2013, Histology and histopathology, 28, 701
  8. 2001, Journal of Biological Chemistry, 276, 5228, 10.1074/jbc.m007542200 · DOI · Paper page
  9. 2006, Circulation Research, 98, 370, 10.1161/01.res.0000202051.28319.c8 · DOI
  10. 2008, American Journal Of Pathology, 173, 1919, 10.2353/ajpath.2008.070875 · DOI
  11. 2011, American Journal of Respiratory Cell and Molecular Biology, 45, 915, 10.1165/rcmb.2010-0113oc · DOI · Paper page
  12. 2012, Journal of Histochemistry & Cytochemistry, 60, 916, 10.1369/0022155412459857 · DOI · Paper page
  13. 2002, Circulation Research, 90, 481, 10.1161/hh0402.105791 · DOI · Paper page
  14. 2009, Reproductive Sciences, 16, 1153, 10.1177/1933719109343310 · DOI
  15. 2007, European Respiratory Journal, 29, 71, 10.1183/09031936.00047905 · DOI
  16. 2013, Current opinion in cell biology, 25, 619, 10.1016/j.ceb.2013.06.003 · DOI · Paper page
  17. 2010, American Journal of Respiratory Cell and Molecular Biology, 43, 109, 10.1165/rcmb.2009-0081oc · DOI
  18. 2005, Journal of Biological Chemistry, 280, 13019, 10.1074/jbc.m411766200 · DOI · Paper page
  19. 2005, Journal of Clinical Investigation, 115, 2223, 10.1172/jci23755 · DOI · Paper page
  20. Sch nherr, 1997, Archives of Biochemistry and Biophysics, 339, 353, 10.1006/abbi.1996.9854 · DOI
  21. 2014, American Journal of Respiratory Cell and Molecular Biology, 51, 26, 10.1165/rcmb.2013-0179oc · DOI
  22. 2010, Journal of Biological Chemistry, 285, 23241, 10.1074/jbc.m109.084673 · DOI · Paper page

Cited by

See all 108

Metadata

Authors
Andersson-Sjoland, A., Hallgren, O., Rolandsson, S., Weitoft, M., Tykesson, E., Larsson-Callerfelt, A.-K., Rydell-Tormanen, K., Bjermer, L., Malmstrom, A., Karlsson, J. C., & Westergren-Thorsson, G.
Affiliations
Lund University (SE)
Corresponding author
Karlsson, J. C.
Venue
Glycobiology
Published
2014-11-03
Volume
25
Issue
3
Pages
243-251
ISSN
  • 0959-6658 (ISSN-L)
  • 1460-2423
OpenAlex
W2155048725
Cited by
98
References
100
Citations by year
2026: 6 · 2025: 4 · 2024: 13 · 2023: 9 · 2022: 8 · 2021: 7 · 2020: 12 · 2019: 6 · 2018: 10 · 2017: 11 · 2016: 8 · 2015: 4
FWCI
0.77
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Glycobiology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion, other-oa)
Funders
  • Lunds Universitet
  • Medical Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
Keywords
versican, proteoglycans, lung inflammation, tissue remodeling, chronic lung disease, asthma, chronic obstructive pulmonary disease, bronchiolitis obliterans syndrome, emphysema, chondroitin sulfate, dermatan sulfate, glycosaminoglycans, TGF-beta, wound healing, cytokine interactions, growth factor interactions
MeSH terms
Animals, Extracellular Matrix, Humans, Lung Diseases, Versicans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Versican in inflammation and tissue remodeling: The impact on lung disorders. https://app.cochat.ai/papers/10.1093/glycob/cwu120
The paper
Andersson-Sjoland, A., Hallgren, O., Rolandsson, S., Weitoft, M., Tykesson, E., Larsson-Callerfelt, A.-K., Rydell-Tormanen, K., Bjermer, L., Malmstrom, A., Karlsson, J. C., & Westergren-Thorsson, G. (2015). Versican in inflammation and tissue remodeling: The impact on lung disorders. Glycobiology. https://doi.org/10.1093/glycob/cwu120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.